Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has received final Part 2 approval from the European Medicines Agency (EMA) for its Phase 3 Clinical Trial Application (CTA) for ‘CT-P44’, a biosimilar candidate to Darzalex, allowing clinical site initiation and patient enrollment in Europe.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Approval of Phase 3 Clinical Trial Plan (Part 2) in Europe for CT-P44 (Darzalex Biosimilar)
- Target Product: CT-P44 (Biosimilar to Darzalex / Darzalex Faspro, Subcutaneous Injection)
- Clinical Trial Phase: Global Phase 3 Clinical Trial
- Target Indication: Refractory or Relapsed Multiple Myeloma
- Filing & Approval Dates (Regulatory Authority):
- Part 2 Application Date: June 18, 2025 (Local time)
- Part 2 Approval Date: August 29, 2025 (Local time / Fact Confirmation Date: August 29, 2025)
- Regulatory Authority: European Medicines Agency (EMA) / EU CT Number: 2024-518588-36-00
- Trial Design & Scale:
- Number of Subjects: 486 patients
- Trial Period: Approx. 2 years
- Trial Design: Double-blind, randomized, active-controlled, parallel-group Phase 3 trial (in combination with lenalidomide and dexamethasone)
- Regulatory Context:
- Under revised EU Clinical Trials Regulation (CTR), full approval of both Part 1 (trial design) and Part 2 (site and execution assessment) enables active clinical trial execution in Europe
- Investment Caution:
- Statistically, the average success rate for clinical-stage drugs reaching final regulatory approval is around 10%
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Patient Dosing and Phase 3 Clinical Progress in Europe
This disclosure confirms that Celltrion has secured final Part 2 approval for its Phase 3 clinical trial plan for CT-P44 in Europe following its earlier Part 1 clearance. With full Part 2 regulatory approval in place, it is key to monitor the initiation of patient recruitment and first-patient dosing at European clinical sites. Tracking subject enrollment and execution of the planned 2-year R&D timeline confirms operational development progress. Clinical progress, patient enrollment milestones, and top-line data updates can be verified through future regulatory filings or upcoming periodic reports (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
